3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase NA
3
Phase 1
2
Phase 4
1
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
505
Urinary Bladder Neoplasms
139
Carcinoma, Renal Cell
117
Neoplasms
67
Kidney Neoplasms
53
Non-Muscle Invasive Bladder Neoplasms
43
Neoplasm Metastasis
38
Carcinoma, Transitional Cell
38
Breast Neoplasms
30
Testicular Neoplasms
28
Recurrence
20
Wilms Tumor
18
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Pain
13
Ovarian Neoplasms
13
Urologic Neoplasms
12
Testicular Germ Cell Tumor
12
Teratoma
12
Seminoma
12
Multiple Myeloma
12
Burkitt Lymphoma
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Lymphoma, Large B-Cell, Diffuse
11
Carcinoma, Ovarian Epithelial
11
Carcinoma
11
Urogenital Neoplasms
10
Neuroblastoma
10
Lymphoma, Non-Hodgkin
10
Lymphoma, Mantle-Cell
10
Lymphoma, Large-Cell, Immunoblastic
10
Interventions
pembrolizumab
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Urogenital Diseases
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled